Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

One-Year Historical Cohort Study of the Phosphate Binder Sucroferric Oxyhydroxide in Patients on Maintenance Hemodialysis.

Kendrick J, Parameswaran V, Ficociello LH, Ofsthun NJ, Davis S, Mullon C, Kossmann RJ, Kalantar-Zadeh K.

J Ren Nutr. 2019 Sep;29(5):428-437. doi: 10.1053/j.jrn.2018.11.002. Epub 2019 Jan 21.

2.

Association of Smoking Status With Mortality and Hospitalization in Hemodialysis Patients.

Li NC, Thadhani RI, Reviriego-Mendoza M, Larkin JW, Maddux FW, Ofsthun NJ.

Am J Kidney Dis. 2018 Nov;72(5):673-681. doi: 10.1053/j.ajkd.2018.04.004. Epub 2018 Jun 15.

PMID:
29909936
3.

Real-World Scenario Improvements in Serum Phosphorus Levels and Pill Burden in Peritoneal Dialysis Patients Treated with Sucroferric Oxyhydroxide.

Kalantar-Zadeh K, Parameswaran V, Ficociello LH, Anderson L, Ofsthun NJ, Kwoh C, Mullon C, Kossmann RJ, Coyne DW.

Am J Nephrol. 2018;47(3):153-161. doi: 10.1159/000487856. Epub 2018 Mar 7.

4.

Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data‚Ä©.

Coyne DW, Ficociello LH, Parameswaran V, Anderson L, Vemula S, Ofsthun NJ, Mullon C, Maddux FW, Kossmann RJ, Sprague SM.

Clin Nephrol. 2017 Aug;88(8):59-67. doi: 10.5414/CN109021.

5.

Intensive hemodialysis associates with improved survival compared with conventional hemodialysis.

Nesrallah GE, Lindsay RM, Cuerden MS, Garg AX, Port F, Austin PC, Moist LM, Pierratos A, Chan CT, Zimmerman D, Lockridge RS, Couchoud C, Chazot C, Ofsthun N, Levin A, Copland M, Courtney M, Steele A, McFarlane PA, Geary DF, Pauly RP, Komenda P, Suri RS.

J Am Soc Nephrol. 2012 Apr;23(4):696-705. doi: 10.1681/ASN.2011070676. Epub 2012 Feb 23.

6.

Survival with three-times weekly in-center nocturnal versus conventional hemodialysis.

Lacson E Jr, Xu J, Suri RS, Nesrallah G, Lindsay R, Garg AX, Lester K, Ofsthun N, Lazarus M, Hakim RM.

J Am Soc Nephrol. 2012 Apr;23(4):687-95. doi: 10.1681/ASN.2011070674. Epub 2012 Feb 23.

7.

Anemia management in patients receiving chronic hemodialysis.

Thakuria M, Ofsthun NJ, Mullon C, Diaz-Buxo JA.

Semin Dial. 2011 Sep-Oct;24(5):597-602. doi: 10.1111/j.1525-139X.2011.00975.x.

PMID:
21999745
8.

Application of kinetic modeling to mineral metabolism management.

Stennett AK, Ofsthun NJ, Gotch FA.

Semin Dial. 2011 Sep-Oct;24(5):580-6. doi: 10.1111/j.1525-139X.2011.00972.x.

PMID:
21999742
9.

International Quotidian Dialysis Registry: Annual report 2010.

Lindsay RM, Suri RS, Moist LM, Garg AX, Cuerden M, Langford S, Hakim R, Ofsthun NJ, McDonald SP, Hawley C, Caskey FJ, Couchoud C, Awaraji C, Nesrallah GE.

Hemodial Int. 2011 Jan;15(1):15-22. doi: 10.1111/j.1542-4758.2010.00521.x. Epub 2011 Jan 14.

PMID:
21231997
10.

Abandoning peracetic acid-based dialyzer reuse is associated with improved survival.

Lacson E Jr, Wang W, Mooney A, Ofsthun N, Lazarus JM, Hakim RM.

Clin J Am Soc Nephrol. 2011 Feb;6(2):297-302. doi: 10.2215/CJN.03160410. Epub 2010 Oct 14.

11.

Outcomes associated with in-center nocturnal hemodialysis from a large multicenter program.

Lacson E Jr, Wang W, Lester K, Ofsthun N, Lazarus JM, Hakim RM.

Clin J Am Soc Nephrol. 2010 Feb;5(2):220-6. doi: 10.2215/CJN.06070809. Epub 2009 Dec 3.

12.

International Quotidian Dialysis Registry: annual report 2009.

Nesrallah GE, Suri RS, Moist LM, Cuerden M, Groeneweg KE, Hakim R, Ofsthun NJ, McDonald SP, Hawley C, Caskey FJ, Couchoud C, Awaraji C, Lindsay RM.

Hemodial Int. 2009 Jul;13(3):240-9. doi: 10.1111/j.1542-4758.2009.00391.x.

PMID:
19703054
13.

Home hemodialysis: a comparison of in-center and home hemodialysis therapy in a cohort of successful home hemodialysis patients.

Sands JJ, Lacson E Jr, Ofsthun NJ, Kay JC, Diaz-Buxo JA.

ASAIO J. 2009 Jul-Aug;55(4):361-8. doi: 10.1097/MAT.0b013e3181aa188e.

PMID:
19506463
14.

The International Quotidian Dialysis Registry: Annual report 2008.

Nesrallah GE, Suri RS, Moist LM, Ofsthun NJ, Hakim R, McDonald SP, Marshall MR, Carter ST, Lindsay RM; International Quotidian Dialysis Registry.

Hemodial Int. 2008 Jul;12(3):281-9. doi: 10.1111/j.1542-4758.2008.00268.x.

PMID:
18638080
15.

Impact of the change in CMS billing rules for erythropoietin on hemoglobin outcomes in dialysis patients.

Ofsthun NJ, Lazarus JM.

Blood Purif. 2007;25(1):31-5. Epub 2006 Dec 14.

PMID:
17170534
16.

The epidemiology of systolic blood pressure and death risk in hemodialysis patients.

Li Z, Lacson E Jr, Lowrie EG, Ofsthun NJ, Kuhlmann MK, Lazarus JM, Levin NW.

Am J Kidney Dis. 2006 Oct;48(4):606-15.

PMID:
16997057
17.

Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival.

Williams ME, Lacson E Jr, Teng M, Ofsthun N, Lazarus JM.

Kidney Int. 2006 Oct;70(8):1503-9. Epub 2006 Aug 30.

18.

Evaluating a new method to judge dialysis treatment using online measurements of ionic clearance.

Lowrie EG, Li Z, Ofsthun NJ, Lazarus JM.

Kidney Int. 2006 Jul;70(1):211-7. Epub 2006 May 24.

19.

To reuse or not to reuse: a tale of 2 studies.

Lowrie EG, Ofsthun NJ.

Am J Kidney Dis. 2006 Feb;47(2):372; author reply 372-3. No abstract available.

PMID:
16431272
20.

Dedicated outpatient vascular access center decreases hospitalization and missed outpatient dialysis treatments.

Mishler R, Sands JJ, Ofsthun NJ, Teng M, Schon D, Lazarus JM.

Kidney Int. 2006 Jan;69(2):393-8.

21.

Antibody response to Engerix-B and Recombivax-HB hepatitis B vaccination in end-stage renal disease.

Lacson E, Teng M, Ong J, Vienneau L, Ofsthun N, Lazarus JM.

Hemodial Int. 2005 Oct;9(4):367-75.

PMID:
16219057
22.

Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.

Collins AJ, Brenner RM, Ofman JJ, Chi EM, Stuccio-White N, Krishnan M, Solid C, Ofsthun NJ, Lazarus JM.

Am J Kidney Dis. 2005 Sep;46(3):481-8.

PMID:
16129210
23.

The online measurement of hemodialysis dose (Kt): clinical outcome as a function of body surface area.

Lowrie EG, Li Z, Ofsthun N, Lazarus JM.

Kidney Int. 2005 Sep;68(3):1344-54.

24.

Measurement of dialyzer clearance, dialysis time, and body size: death risk relationships among patients.

Lowrie EG, Li Z, Ofsthun N, Lazarus JM.

Kidney Int. 2004 Nov;66(5):2077-84.

25.

Dialysis dose and gender: a different hypothesis.

Lowrie EG, Ofsthun N, Li Z.

Kidney Int. 2004 Sep;66(3):1291-2; author reply 1292. No abstract available.

26.

Reprocessing dialysers for multiple uses: recent analysis of death risks for patients.

Lowrie EG, Li Z, Ofsthun N, Lazarus JM.

Nephrol Dial Transplant. 2004 Nov;19(11):2823-30. Epub 2004 Aug 17.

PMID:
15316099
27.

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM.

J Am Soc Nephrol. 2004 Aug;15(8):2208-18.

28.

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.

Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R.

N Engl J Med. 2003 Jul 31;349(5):446-56.

29.

The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients.

Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM.

Kidney Int. 2003 May;63(5):1908-14.

30.

The association between mental health, physical function, and hemodialysis mortality.

Knight EL, Ofsthun N, Teng M, Lazarus JM, Curhan GC.

Kidney Int. 2003 May;63(5):1843-51.

31.

Effect of variability in anemia management on hemoglobin outcomes in ESRD.

Lacson E Jr, Ofsthun N, Lazarus JM.

Am J Kidney Dis. 2003 Jan;41(1):111-24.

PMID:
12500228
32.

Body size, dialysis dose and death risk relationships among hemodialysis patients.

Lowrie EG, Li Z, Ofsthun N, Lazarus JM.

Kidney Int. 2002 Nov;62(5):1891-7.

33.

Limitations of membrane structure and dialyzer design on large solute removal in dialysis.

Ofsthun NJ.

Blood Purif. 2000;18(4):264-6. Review. No abstract available.

PMID:
10965066
34.

Potential of dual-skinned, high-flux membranes to reduce backtransport in hemodialysis.

Soltys PJ, Zydney A, Leypoldt JK, Henderson LW, Ofsthun NJ.

Kidney Int. 2000 Aug;58(2):818-28.

35.

Beyond bloodletting.

Ofsthun NJ.

Blood Purif. 1998;16(3):121-2. No abstract available.

PMID:
9681153
36.

The effect of blood contact and reuse on the transport properties of high-flux dialysis membranes.

Kunas GA, Burke RA, Brierton MA, Ofsthun NJ.

ASAIO J. 1996 Jul-Aug;42(4):288-94.

PMID:
8828786
37.

Ultrafiltration and backfiltration during hemodialysis.

Ofsthun NJ, Leypoldt JK.

Artif Organs. 1995 Nov;19(11):1143-61. Review.

PMID:
8579527
38.

Importance of convection in artificial kidney treatment.

Ofsthun NJ, Zydney AL.

Contrib Nephrol. 1994;108:53-70. Review. No abstract available.

PMID:
8039398
39.
40.

Pathways for fluid loss from the peritoneal cavity.

Shockley TR, Ofsthun NJ.

Blood Purif. 1992;10(3-4):115-21. Review.

PMID:
1308677
41.
42.

Visual evidence of concentration polarization in cross-flow membrane plasmapheresis.

Ofsthun NJ, Colton CK.

ASAIO Trans. 1987 Jul-Sep;33(3):510-7. No abstract available.

PMID:
3675981

Supplemental Content

Loading ...
Support Center